Legend Biotech (LEGN) Income from Discontinued Operations (2022 - 2025)
Legend Biotech's (LEGN) quarterly Income from Discontinued Operations came in at 11200000.0 in Q4 2025, up 21.13% YoY from 9246511.63 in Q4 2024, and up 21.13% on a QoQ basis from 14200000.0 in Q4 2024.
Legend Biotech (LEGN) Income from Discontinued Operations (2022 - 2025) Analysis & Trends
Legend Biotech (LEGN) has 4 years of Income from Discontinued Operations data on file, last reported at 11200000.0 in Q4 2025.
- Quarterly Income from Discontinued Operations rose 21.13% year-over-year to 11200000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 25551006.0 (changed N/A YoY) and the FY2025 annual result came in at 14200000.0, up 24.87% from the prior year.
- Income from Discontinued Operations climbed to 11200000.0 in Q4 2025, from 14200000.0 in the prior quarter.
- In the past five years, Income from Discontinued Operations ranged from a high of 1994.0 in Q4 2023 to a low of 14200000.0 in Q4 2024.
- A 4-year average of 6387751.5 and a median of 5676500.0 in 2022 frame the typical range for Income from Discontinued Operations.
- Annual changes were most pronounced in 2023 — Income from Discontinued Operations soared 101.3% — and 2024, when it tumbled 712236.41%.
- Tracing LEGN's Income from Discontinued Operations over 4 years: stood at 153000.0 in 2022, then surged by 101.3% to 1994.0 in 2023, then plunged by 712236.41% to 14200000.0 in 2024, then grew by 21.13% to 11200000.0 in 2025.
- The last three Income from Discontinued Operations figures came in at 11200000.0 (Q4 2025), 14200000.0 (Q4 2024), and 1994.0 (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -11.20 Mn |
| Dec 31, 2024 | -14.20 Mn |
| Dec 31, 2023 | 1,994.00 |
| Dec 31, 2022 | -153,000.00 |